According to the latest industry report, the global food allergy treatment market is poised for remarkable growth, reaching a projected USD 12.57 billion by 2032, up from USD 6.51 billion in 2024, at a compound annual growth rate (CAGR) of 8.62% during the forecast period of 2025–2032. A rise in the global prevalence of food allergies, particularly among children, combined with technological progress in diagnostics and immunotherapy, is contributing to this upward trajectory.
Evolving Treatment Landscape and Driving Factors
The food allergy treatment market is witnessing significant transformation. From conventional antihistamines and epinephrine auto-injectors to newer modalities like oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT), the treatment arsenal is rapidly expanding. Innovations such as Palforzia (the first FDA-approved peanut allergy immunotherapy) and improved epinephrine delivery systems like EpiPen are creating a robust ecosystem for managing life-threatening food allergies.
Explore Market Dynamics: Request Your Sample Report Now! https://www.snsinsider.com/sample-request/7288
Key growth drivers include:
- Rising prevalence of food allergies in both developed and emerging economies.
- Growing awareness through school programs, social media, and government health initiatives.
- Expanding investments in R&D for new therapies.
- Favorable regulatory pathways promoting faster approval of novel treatments.
North America Leads, But Asia-Pacific Emerges as Fastest Growing
North America continues to dominate the global market with a 40.7% market share in 2024, primarily due to its high awareness levels, established healthcare systems, and rapid adoption of immunotherapy. In particular, the United States, valued at USD 2.39 billion in 2024, is expected to nearly double to USD 4.43 billion by 2032 at a CAGR of 8.06%.
According to NCBI, nearly 32 million Americans, including 6 million children, suffer from food allergies. These alarming figures are spurring urgent demand for advanced treatments and driving public-private collaborations in the region.
Meanwhile, Asia-Pacific is projected to grow at a CAGR of 9.30%, driven by urbanization, dietary westernization, and increasing food sensitivity among populations in countries such as China, India, and Japan. Public health campaigns, improved diagnostics, and government policies aimed at awareness are gradually addressing the long-standing issue of underdiagnosis.
In Europe, countries like the U.K., Germany, and France are enhancing clinical trial activity, strengthening regulatory frameworks, and increasing adoption of both OIT and EPIT therapies. The region is also witnessing significant strides in public education, allergen labeling, and school-based allergy management programs.
Drive Your Business Forward with Key Insights Enquire Now Report! https://www.snsinsider.com/enquiry/7288
Key Takeaways:
- North America held approximately 40.7% of the global food allergy treatment market in 2024.
- U.S. remains a dominant market due to FDA approvals (e.g., Palforzia), early access to epinephrine auto-injectors, and widespread screening.
- Asia-Pacific is the fastest-growing region at 9.30% CAGR, fueled by rising allergy prevalence and increasing healthcare investment.
- Europe is gaining traction through clinical innovation, collaborative R&D, and rising awareness.
- Latin America and MEA regions show moderate growth potential due to healthcare infrastructure development and emerging awareness.
Competitive Landscape
Prominent players operating in the global food allergy treatment market include:
- Aimmune Therapeutics
- DBV Technologies
- ALK-Abelló
- Stallergenes Greer
- Camallergy
- Alladapt Immunotherapeutics
- Aravax
- Intrommune Therapeutics
- Prota Therapeutics
- Regeneron Pharmaceuticals
These companies are aggressively expanding their portfolios through strategic partnerships, clinical advancements, and patient-focused innovations.
Recent Developments Pushing the Market Forward
The global landscape is marked by dynamic innovation, strong partnerships, and strategic launches:
- January 2025 – DBV Technologies announced positive 24-month data from its Open-Label Extension (OLE) Phase 3 EPITOPE trial, showing continued efficacy of VIASKIN Peanut 250 µg (VP250) for children aged 1–3 years.
- June 2024 – ALK-Abelló introduced its “Allergy+” strategy to solidify its leadership in the food allergy and anaphylaxis treatment segments, extending its focus into high unmet needs across adjacent allergic diseases.
Stay Ahead with Cutting-Edge Business Insights, Get Our Request Checkout Now! https://www.snsinsider.com/checkout/7288
Market Segmentation Overview
The food allergy treatment market has been segmented to better understand consumer needs and technological capabilities:
By Allergen Type:
- Dairy Products
- Poultry Products
- Tree Nuts
- Peanuts
- Shellfish
- Wheat
- Soy
- Others
By Drug Type:
- Antihistamines
- Epinephrine
- Immunotherapy
By Route of Administration:
- Parenteral
- Oral
- Topical
By End-Use:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Regional Coverage:
- North America: U.S., Canada, Mexico
- Europe: Germany, France, U.K., Italy, Spain, Poland, Turkey
- Asia Pacific: China, India, Japan, South Korea, Singapore, Australia
- Middle East & Africa: UAE, Saudi Arabia, South Africa
- Latin America: Brazil, Argentina
Conclusion
The global food allergy treatment market stands at a pivotal moment. As food allergies continue to impact millions globally, innovative treatments and improved diagnostics are offering hope for better management and quality of life. With North America setting the pace, Asia-Pacific gaining speed, and Europe pushing regulatory excellence, the future of food allergy care looks more comprehensive and inclusive than ever before.
Stakeholders—including pharmaceutical companies, policymakers, healthcare providers, and investors—are encouraged to seize the opportunities presented by this rapidly evolving market to foster innovation and improve patient outcomes on a global scale.
Table of Contents:
- Introduction
- Executive Summary
- Research Methodology
- Market Dynamics Impact Analysis
- Statistical Insights and Trends Reporting
- Competitive Landscape
- Food Allergy Treatment Market Segmentation by Allergen Type
- Food Allergy Treatment Market Segmentation by Drug Type
- Food Allergy Treatment Market Segmentation by Route of Administration
- Food Allergy Treatment Market Segmentation by End-User
- Regional Analysis
- Company Profiles
- Use Cases and Best Practices
- Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Mail us: [email protected]
